Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Core Insights - Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative treatments for serious autoimmune and inflammatory diseases [1][3] - The company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and will hold one-on-one investor meetings on the same day [1] Company Overview - Zura is developing dual-pathway antibodies aimed at addressing unmet needs in autoimmune and inflammatory diseases [3] - The company's pipeline includes candidates targeting immune system imbalances to enhance efficacy, safety, and dosing convenience [3] Product Pipeline - Zura's lead product candidate, tibulizumab (ZB-106), is currently in two Phase 2 clinical studies: TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis [4] - Additional candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for various autoimmune and inflammatory conditions [4]